Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 10 OCTOBER 2020

Cleantech Research And Development Important For COVID-19 Economic Recovery

Smart & Biggar
Explore more from Smart & Biggar

The Canadian government has acknowledged that it views COVID-19 as "an opportunity to rethink and optimize the way we do things".

CanadaCoronavirus (COVID-19)
Noel Courage
Noel Courage
Author LinkedIn connections

The Canadian government has acknowledged that it views COVID-19 as "an opportunity to rethink and optimize the way we do things". While clean technology has been a priority in Canada's economic growth for some time, accelerating the transition to cleantech and clean energy alternatives presents an opportunity to restart the economy after the challenges faced during the COVID-19 pandemic.

Cleantech companies currently employ nearly 200,000 Canadians, and continued growth is expected to help create even more well-paying jobs. Cleantech research and development can also lead to manufacturing and distribution, and innovative cleantech solutions have the potential to generate significant economic benefits for the Canadian export industry. As a result, supporting cleantech research and development not only contributes to positive environmental impacts and building healthier communities, it also supports jobs and Canada's economic growth as it recovers from the effects of

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Health Canada Updates Policies On Foreign Regulatory Actions, Summary Reporting, Compliance & Enforcement And Requests For New Data

Health Canada issued revised guidance on notifying Health Canada of foreign actions, effective October 1, 2026. The revised guidance clarifies the requirements to notify Health Canada of certain foreign regulatory actions specified in subsection C.01.050(2) of the Food and Drug Regulations in the specified foreign jurisdictions, which involve a serious risk of injury to human health and are relevant to the safety of the drug.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

Health Canada Obtains Permanent Injunction To Prevent Illegal Sale Of Injectable Peptides By Canlab Research

Health Canada has secured a permanent injunction against Canlab Research, a Quebec-based online retailer, preventing the company from manufacturing, distributing, or selling unauthorized injectable peptides in Canada. This enforcement action follows years of regulatory warnings and provisional court orders aimed at stopping the illegal sale of peptide drugs promoted with unproven health claims for anti-aging, weight loss, and athletic performance.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar
Article

A KTEP Ahead: Canada's New Mechanism For Advanced Examination Of Patent Applications

For a Canadian patent application to be examined, an applicant must file a request for examination with the Canadian Intellectual Property Office (CIPO). In most cases, the order in which applications are examined is based on the order that the requests for examination are received. An applicant may be able to accelerate examination of their patent application through several existing mechanisms, including advancing examination via special order, accelerating examination of applications related to green technology, and the Patent Prosecution Highway (PPH).
CanadaIntellectual Property
Smart & Biggar
Smart & Biggar
Article

Pharmaceutical And Life Sciences Sector Task Force Submits Final Report To The Ministers Of Health And Industry

The Pharmaceutical and Life Sciences Sector Task Force has released its final report addressing Canada's challenges in medication access, regulatory processes, and life sciences competitiveness. The report examines structural issues including lengthy reimbursement pathways, underperforming clinical trial environments, and erosion of domestic investment, while proposing 39 recommendation areas to strengthen Canada's health sovereignty and industrial strategy.
CanadaFood, Drugs, Healthcare, Life Sciences
Smart & Biggar
Smart & Biggar